Study Results
The aim of this work was to evaluate the protection against a virulent infectious bursal disease virus (IBDV) challenge in SPF chickens vaccinated with a recombinant avian adeno-associated virus expressing the VP2 protein (rAAAV-VP2) of IBDV, and to compare with commercial intermediate classic IBDV vaccination. Transgenic expression of the VP2 protein after rAAAV-VP2 vaccination induced protective immunity against IBDV challenge in 80% of the birds, without compromising the bursa of Fabricius (Figure 1 ).
Significance of Study Results
The use of rAAAV virions for gene delivery represents a novel approach to poultry vaccination. Overall, this experiment demonstrated the potential of vaccination with the rAAAV-VP2 virions for use in young chickens.
Additional Information
IBDV is the etiological agent of the worldwide distributed infectious bursal disease, also known as Gumboro disease. Very virulent IBDV strains emerged in Europe in the late eighties, they can cause up to 60% mortality and are now considered a threat in several countries worldwide.
Control of IBDV is currently attempted using live and killed vaccines for the dams and/or offspring. Immunization of chickens against IBDV with viral vectors expressing the VP2 has been previously reported and includes using avian herpesvirus, fowlpox virus, Newcastle disease virus and fowl adenovirus as expression systems. The advantages of the recombinant technology include safety (no reversion to pathogenicity of vaccine virus), that the vaccine can be tailor made to match field virus phenotype increasing its efficacy and that a vaccine based on VP2 alone should allow monitoring of the field situation by the discrimination between antibody induced by vaccination and by field infection.
The bursal tissue integrity observed after rAAAV-VP2 vaccination correlates with the expectation of an adequate response to vaccination programs or field challenges after initial IBDV vaccination. Therefore, early and frequent vaccination with intermediate or intermediate plus vaccines can induce high levels of IBDV neutralizing antibodies, but can also deploy the bursal B cell population generating problems with immune responses against other pathogens and failure of vaccination programs.
This pilot study only evaluated the protection after parenteral application and against classical IBDV viruses, nevertheless, initial investigations revealed a humoral immune response after in ovo application of rAAAV-VP2 particles. Although the 80% protection obtained in this trial is close to the 90% protection expected in an efficacy test for IBDV vaccines, the number of birds used in this proof of concept study was limited and further trials including a larger number of birds are required. 
